NCT04039347 (BOSTON-3) is a Phase 3 clinical trial of Liposomal Cyclosporine A 5 mg in Bronchiolitis Obliterans, sponsored by Zambon SpA.

Who is sponsoring NCT04039347?

NCT04039347 is sponsored by Zambon SpA.

What drugs are being tested in NCT04039347?

Interventions in NCT04039347: Liposomal Cyclosporine A 5 mg, Liposomal Cyclosporine A 10 mg.

What condition does NCT04039347 study?

NCT04039347 studies Bronchiolitis Obliterans, Obliterative Bronchiolitis, Bronchiolitis Obliterans Syndrome.

Is NCT04039347 still recruiting?

NCT04039347 is currently terminated. Last updated 7 April 2026.

Last reviewed 2026-04-07 · How we verify

NCT04039347: BOSTON-3

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)

Terminated Phase 3 Last updated 7 April 2026

What this trial tests

Phase 3 trial testing Liposomal Cyclosporine A 5 mg in Bronchiolitis Obliterans in 164 participants. Terminated before completion.

Timeline

12 March 2020

Primary endpoint
25 February 2026

25 February 2026

Quick facts

Lead sponsor	Zambon SpA
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	164
Start date	12 March 2020
Primary completion	25 February 2026
Estimated completion	25 February 2026
Sites	37 locations across France, Denmark, Belgium, Austria, United Kingdom, Germany, Israel, United States

Drugs / interventions tested

Liposomal Cyclosporine A 5 mg — full drug profile →
Liposomal Cyclosporine A 10 mg — full drug profile →

Conditions studied

Bronchiolitis Obliterans — all drugs for Bronchiolitis Obliterans →
Obliterative Bronchiolitis — all drugs for Obliterative Bronchiolitis →
Bronchiolitis Obliterans Syndrome — all drugs for Bronchiolitis Obliterans Syndrome →

Sponsor

Zambon SpA — full company profile →

Who can join

18 and older, any sex, with Bronchiolitis Obliterans or Obliterative Bronchiolitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the trial is to assess the long-term safety and efficacy of L-CsA plus Standard of Care (SoC) in the treatment of BOS in single (SLT) and double lung transplant (DLT) recipients.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Bronchiolitis obliterans syndrome after lung or haematopoietic stem cell transplantation: current management and future directions.
Glanville AR, Benden C, Bergeron A, Cheng GS, et al · · 2022 · cited 36× · PMID 35898810 · DOI 10.1183/23120541.00185-2022
Advancing Medicine with Lipid-Based Nanosystems-The Successful Case of Liposomes.
Luiz H, Oliveira Pinho J, Gaspar MM. · · 2023 · cited 27× · PMID 36830971 · DOI 10.3390/biomedicines11020435
Lymphocyte Depleting and Modulating Therapies for Chronic Lung Allograft Dysfunction.
Bos S, Pradère P, Beeckmans H, Zajacova A, et al · · 2023 · cited 5× · PMID 37295951 · DOI 10.1124/pharmrev.123.000834

Verify or expand the search:

Other recruiting trials for Bronchiolitis Obliterans

Currently open trials in the same condition.

NCT07316829 — TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlation With Re · active not recruiting
NCT05922761 — BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) · Phase 2 · recruiting
NCT04604522 — Evaluating Clonogenic Epithelial Cell Populations in Patients With Bronchiolitis Obliterans Syndrome · recruiting

Other Zambon SpA trials

Trials by the same sponsor.

NCT06503770 — A Retrospective Chart Review Study of Patients With Chronic Lung Allograft Dysfunction-Bronchiolitis Obliterans Syndrome · completed
NCT03887221 — A Single and Multiple Dose Study to Assess How the Drug Enters, Moves Through and Exits the Body, Safety and Tolerabilit · Phase 1 · completed
NCT04107675 — A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4) · Phase 2 · terminated
NCT04229303 — Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects · Phase 1 · completed
NCT03994328 — An Observational Study on Safinamide, Rasagiline and Other Standard of Care in PD · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04039347 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zambon SpA
Last refreshed: 7 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04039347.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing